Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Western Pennsylvania Cancer Institute at Western Pennsylvania Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
UPMC Cancer Center at UPMC Passavant
mi
from
Pittsburgh, PA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
UPMC Cancer Center at UPMC Passavant
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
St. Clair Memorial Hospital Cancer Center
mi
from
Pittsburgh, PA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
St. Clair Memorial Hospital Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Washington Hospital Cancer Center
mi
from
Washington, PA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Washington Hospital Cancer Center
mi
from
Washington, PA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
M. D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Methodist Hospital
mi
from
Houston, TX
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Methodist Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Surgical Oncology Associates
mi
from
Newport News, VA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Surgical Oncology Associates
mi
from
Newport News, VA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Providence Cancer Center at Sacred Heart Medical Center
mi
from
Spokane, WA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Providence Cancer Center at Holy Family Hospital
mi
from
Spokane, WA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Providence Cancer Center at Holy Family Hospital
mi
from
Spokane, WA
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
United Hospital Center
mi
from
Clarksburg, WV
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
United Hospital Center
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
mi
from
Huntington, WV
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
Edwards Comprehensive Cancer Center at Cabell Huntington Hospital
mi
from
Huntington, WV
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated:  2/21/2018
UPMC - Moon
mi
from
Moon, PA
Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage I Rectal Cancer
A Phase II Trial of Chemoradiotherapy and Local Excision for uT2uN0 Rectal Cancer
Status: Enrolling
Updated: 2/21/2018
UPMC - Moon
mi
from
Moon, PA
Click here to add this to my saved trials
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated:  2/21/2018
Dent Neurosciences Research Center
mi
from
Amherst, NY
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated: 2/21/2018
Dent Neurosciences Research Center
mi
from
Amherst, NY
Click here to add this to my saved trials
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated:  2/21/2018
Atlantic Neuroscience Institute - Brain Tumor Center of NJ
mi
from
Summit, NJ
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated: 2/21/2018
Atlantic Neuroscience Institute - Brain Tumor Center of NJ
mi
from
Summit, NJ
Click here to add this to my saved trials
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated:  2/21/2018
University of California, San Francisco, Division of Neuro-Oncology
mi
from
San Francisco, CA
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated: 2/21/2018
University of California, San Francisco, Division of Neuro-Oncology
mi
from
San Francisco, CA
Click here to add this to my saved trials
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated:  2/21/2018
Kaiser Permanente Los Angeles Medical Center
mi
from
Los Angeles, CA
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated: 2/21/2018
Kaiser Permanente Los Angeles Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated:  2/21/2018
Mayo Clinic Cancer Center
mi
from
Rochester, MN
VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM
A Pivotal Randomized, Controlled Trial of VAL-083 in Patients With Recurrent Glioblastoma Who Have Failed Standard Temozolomide/Radiation Therapy and Bevacizumab (STAR-3)
Status: Enrolling
Updated: 2/21/2018
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers
Being Present: Audio-Based Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers
Status: Enrolling
Updated:  2/22/2018
University of California at San Francisco
mi
from
San Francisco, CA
Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers
Being Present: Audio-Based Mindfulness Meditation Intervention for Colorectal Cancer Patients and Caregivers
Status: Enrolling
Updated: 2/22/2018
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated:  2/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
A Phase 1 Dose-Escalation and Pharmacokinetic Study of NC-4016 in Patients With Advanced Solid Tumors or Lymphoma
Status: Enrolling
Updated: 2/22/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Status: Enrolling
Updated:  2/23/2018
Santa Monica Sarcoma Center
mi
from
Santa Monica, CA
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Status: Enrolling
Updated: 2/23/2018
Santa Monica Sarcoma Center
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Status: Enrolling
Updated:  2/23/2018
MD Anderson Sarcoma Center
mi
from
Houston, TX
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Status: Enrolling
Updated: 2/23/2018
MD Anderson Sarcoma Center
mi
from
Houston, TX
Click here to add this to my saved trials
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Status: Enrolling
Updated:  2/23/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Paclitaxel + Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Paclitaxel in Combination With Bevacizumab (Avastin) for the Treatment of Metastatic or Unresectable Angiosarcoma
Status: Enrolling
Updated: 2/23/2018
Stanford Univ Med Ctr
mi
from
Stanford, CA
Click here to add this to my saved trials
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Status: Enrolling
Updated:  2/23/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer
Status: Enrolling
Updated: 2/23/2018
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Bay Area Tumor Institute
mi
from
Oakland, CA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Bay Area Tumor Institute
mi
from
Oakland, CA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
UCSF Medical Center at Mount Zion
mi
from
San Francisco, CA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Exempla Saint Joseph Hospital
mi
from
Denver, CO
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Exempla Saint Joseph Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Delaware Clinical & Laboratory Physicians, PA
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Delaware Clinical & Laboratory Physicians, PA
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Helen F. Graham Cancer Center
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Helen F. Graham Cancer Center
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Medical Oncology Hematology Consultants
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Medical Oncology Hematology Consultants
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Regional Hematology and Oncology PA
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Regional Hematology and Oncology PA
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Christiana Care Health System - Christiana Hospital
mi
from
Newark, DE
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
University of Iowa - Holden Comprehensive Cancer Center
mi
from
Iowa City, IA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Saint Elizabeth Medical Center South
mi
from
Edgewood, KY
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Saint Elizabeth Medical Center South
mi
from
Edgewood, KY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Saint Elizabeth Fort Thomas
mi
from
Fort Thomas, KY
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Saint Elizabeth Fort Thomas
mi
from
Fort Thomas, KY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Baptist Health Lexington
mi
from
Lexington, KY
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Baptist Health Lexington
mi
from
Lexington, KY
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Northwest Hospital Center
mi
from
Randallstown, MD
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Northwest Hospital Center
mi
from
Randallstown, MD
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Sparrow Hospital
mi
from
Lansing, MI
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Mayo Clinic Cancer Center
mi
from
Rochester, MN
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Saint Luke's Hospital, Kansas City
mi
from
Kansas City, MO
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Missouri Baptist Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Margaret R Pardee Memorial Hospital
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated:  2/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Phase II Study of Neoadjuvant Letrozole for Postmenopausal Women With Estrogen Receptor Positive Ductal Carcinoma In SITU (DCIS)
Status: Enrolling
Updated: 2/26/2018
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials